UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Clinical pharmacokinetics, 2017-03, Vol.56 (3), p.235-250

2017

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

Clinical pharmacokinetics, 2019-09, Vol.58 (9), p.1131-1147

2019

Volltextzugriff (PDF)

Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition

Hypertension (Dallas, Tex. 1979), 2010-09, Vol.56 (3), p.490-497

2010

Volltextzugriff (PDF)

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

Clinical pharmacokinetics, 2013-12, Vol.52 (12), p.1101-1109

2013

Volltextzugriff (PDF)

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone

The European respiratory journal, 2019-01, Vol.53 (1), p.1801060

2019

Volltextzugriff (PDF)

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study

Journal of clinical psychopharmacology, 2023-03, Vol.43 (2), p.113-121

2023

Volltextzugriff (PDF)

Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant

Hypertension (Dallas, Tex. 1979), 2008-02, Vol.51 (2), p.211-217

2008

Volltextzugriff (PDF)

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2015-03, Vol.17 (3), p.430-439

2015

Volltextzugriff (PDF)

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

Cancer chemotherapy and pharmacology, 2014-04, Vol.73 (4), p.759-770

2014

Volltextzugriff (PDF)

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

Breast cancer research and treatment, 2012-06, Vol.133 (3), p.1057-1065

2012

Volltextzugriff (PDF)

PHARMACOKINETICS OF SINGLE AND MULTIPLE RISING DOSES OF BI 425809, A NEW GLYT1 INHIBITOR, IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS

Alzheimer's & dementia, 2016-07, Vol.12 (7), p.P425-P425

2016

Volltextzugriff (PDF)

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Clinical drug investigation, 2018-08, Vol.38 (8), p.737-750

2018

Volltextzugriff (PDF)

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

Clinical drug investigation, 2014-03, Vol.34 (3), p.173-182

2014

Volltextzugriff (PDF)

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study

European journal of drug metabolism and pharmacokinetics, 2018-04, Vol.43 (2), p.239-249

2018

Volltextzugriff (PDF)

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

Clinical and translational science, 2018-11, Vol.11 (6), p.616-623

2018

Volltextzugriff (PDF)

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

European journal of drug metabolism and pharmacokinetics, 2017-06, Vol.42 (3), p.461-469

2017

Volltextzugriff (PDF)

A Drug–Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

European journal of drug metabolism and pharmacokinetics, 2022-01, Vol.47 (1), p.81-89

2022

Volltextzugriff (PDF)

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

European journal of drug metabolism and pharmacokinetics, 2022-01, Vol.47 (1), p.91-103

2022

Volltextzugriff (PDF)

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Breast cancer research and treatment, 2012-08, Vol.134 (3), p.1149-1159

2012

Volltextzugriff (PDF)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Cancer chemotherapy and pharmacology, 2014-08, Vol.74 (2), p.267-275

2014

Volltextzugriff (PDF)

Role of NADPH Oxidase in the Endothelial Dysfunction and Oxidative Stress in Aorta of Aged Spontaneous Hypertensive Rats

Iranian journal of basic medical sciences, 2010-04, Vol.13 (2), p.48

2010

Volltextzugriff (PDF)

P1‐061: Pharmacokinetics of Single and Multiple Rising Doses of BI 425809, A New Glyt1 Inhibitor, in Young and Elderly Healthy Volunteers

Alzheimer's & dementia, 2016-07, Vol.12 (7S_Part_8), p.P425-P425

2016

Volltextzugriff (PDF)

Role of NADPH Oxidase in the Endothelial Dysfunction and Oxidative Stress in Aorta of Aged Spontaneous Hypertensive Rats

Iranian journal of basic medical sciences, 2010-04, Vol.13 (45)

2010

Volltextzugriff (PDF)

PHARMACOKINETICS OF SINGLE AND MULTIPLE RISING DOSES OF BI 425809, A NEW GLYT1 INHIBITOR, IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS

Alzheimer's & dementia, 2016, Vol.12 (7), p.P425-P425

2016

Volltextzugriff (PDF)

A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors

Future oncology (London, England), 2015-05, Vol.11 (10), p.1479-1491

2015

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(37)

Publikationsform

Sprache

Englisch
(35)
Deutsch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(24)
Humans
(17)
Male
(13)
Middle Aged
(13)
Pharmacology & Pharmacy
(13)
Adult
(11)
Female
(11)
Pharmacology/toxicology
(11)
Aged
(10)
Medicine
(10)
Medicine & Public Health
(9)
Quinazolines - Pharmacokinetics
(8)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Original Research Article
(7)
Quinazolines - Administration & Dosage
(7)
Afatinib
(6)
Area Under Curve
(6)
Oncology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

Oxidative Stress and Endothelial Dysfunction in Aortas of Aged Spontaneously Hypertensive Rats by NOX1/2 Is Reversed by NADPH Oxidase Inhibition

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone

Pharmacokinetic-Interactions of BI 425809, a Novel Glycine Transporter 1 Inhibitor, With Cytochrome P450 and P-Glycoprotein Substrates: Findings From In Vitro Analyses and an Open-Label, Single-Sequence Phase I Study

Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

PHARMACOKINETICS OF SINGLE AND MULTIPLE RISING DOSES OF BI 425809, A NEW GLYT1 INHIBITOR, IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokinetics

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

A Drug–Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Role of NADPH Oxidase in the Endothelial Dysfunction and Oxidative Stress in Aorta of Aged Spontaneous Hypertensive Rats

P1‐061: Pharmacokinetics of Single and Multiple Rising Doses of BI 425809, A New Glyt1 Inhibitor, in Young and Elderly Healthy Volunteers

Role of NADPH Oxidase in the Endothelial Dysfunction and Oxidative Stress in Aorta of Aged Spontaneous Hypertensive Rats

PHARMACOKINETICS OF SINGLE AND MULTIPLE RISING DOSES OF BI 425809, A NEW GLYT1 INHIBITOR, IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS

A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors

Suchergebnisse filtern